NCT03359850View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 20, 2018

Primary Completion Date

September 16, 2019

Study Completion Date

June 24, 2020

Conditions

Ovarian NeoplasmsNeoplasmsSolid TumorHepatic Impairment

Interventions

DRUG

Niraparib

Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.

Trial Locations (5)

30322

GSK Investigational Site, Atlanta

77030

GSK Investigational Site, Houston

80045

GSK Investigational Site, Aurora

90033

GSK Investigational Site, Los Angeles

92663

GSK Investigational Site, Newport Beach

All Listed Sponsors

lead

Tesaro, Inc.

INDUSTRY

NCT03359850 - Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients | Biotech Hunter | Biotech Hunter